以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 证券之星消息，爱朋医疗(300753)11月13日在投资者关系平台上答复投资者关心的问题。 投资者提问：工信部：中试平台应聚焦培育壮大新兴产业、布局建设未来产业等任务 加快产业科技创 新成果向现实生产力转化】智通财经11月11日电，工业和信息化部办公厅发布《制造业中试平台建设指 引（2025版）》。其中提出，中试平台应围绕加快推进新型工业化、建设制造强国战略需求，聚焦改造 提升传统产业、培育壮大新兴产业、布局建设未来产业的任务，加快产业科技创新成果向现实生产力转 化。在脑机接口、贵如何在脑机接口大发展？ 爱朋医疗回复：您好，国家政策正在助力脑机接口行业加速发展。公司将持续巩固自身技术平台，积累 和提升相关核心技术和核心竞争力，在脑机接口领域持续推进围术期脑状态监测、多动症、睡眠疾病诊 治、癫痫等精神类疾病诊疗的临床创新应用。谢谢。 ...

每经AI快讯，有投资者在投资者互动平台提问：（五）丰富民生领域应用场景 医疗卫生领域。推动大 数据、物联网、脑机接口等新一代信息技术及医疗机器人等智能设备集成应用，创新健康咨询、问诊指 引、辅助诊断、远程医疗、用药审核等医疗应用场景。 养老助残托育领域。创新服务机器人、智能可 穿戴设备、远程终端服务系统、在线家庭医生药师等应用场景，打造科技助残、家政服务、托育照护、 康复医疗、健康服务等相结合的生活服务场景。 贵司在这方面有什么产品？ （记者 曾健辉） 爱朋医疗（300753.SZ）11月13日在投资者互动平台表示，您好，公司在医疗卫生领域积极推动新一代 信息技术的应用，尤其在脑机接口技术方面，公司推出了顽固性失眠麻醉治疗系统，该系统针对顽固性 失眠麻醉睡眠诊疗临床需求而设计；多模态ADHD行为训练系统，采用科学脑电监测、多模态干预训练 等方式，帮助儿童逐步改善多动及注意缺陷行为，提升专注力。在养老助残托育领域，公司通过参股常 州瑞神安，布局了脑神经调控及颅内植入电极等医疗器械产品的研发、生产及销售，包括一次性使用颅 内脑电极（SEEG）、植入式迷走神经刺激器（VNS）、植入式可充电脊髓刺激器（SCS）及植入 ...

Healthcare Policy - National Healthcare Security Administration held a series of discussions on the adjustment of the disease-based payment grouping scheme 3.0, involving over 70 representatives from medical institutions and industry associations [1] Drug and Medical Device Approvals - Shijiazhuang Pharmaceutical Group's application for the listing of Pertuzumab injection has been accepted by the National Medical Products Administration, targeting HER2-positive breast cancer [1] - Huason Pharmaceutical received a registration certificate for its special medical purpose formula food, Ganyimei®, designed for patients over 10 years old with strict fat restrictions and digestive absorption disorders [2] - United Imaging Healthcare's subsidiary obtained a medical device registration certificate for its color Doppler ultrasound diagnostic system, enhancing its product range across various market segments [3] - Yiling Pharmaceutical's application for the listing of Memantine Hydrochloride, a drug for treating moderate to severe Alzheimer's disease, has been approved [4] - Zhifei Biological's clinical trial application for a freeze-dried varicella inactivated vaccine has been accepted by the National Medical Products Administration [10] - Changchun High-tech's subsidiary received approval for a clinical trial of an acellular pertussis-diphtheria-tetanus combined vaccine for adolescents and adults [11] Capital Market Activities - Peking University Pharmaceutical announced the release of 34,615,386 shares from pledge, representing 51.52% of the pledged shares and 5.81% of the total share capital [5] - Kelun Pharmaceutical received approval for a registration of 4 billion yuan in ultra-short-term financing bonds, with a validity period of 2 years [6][7] - Baili Tianheng decided to delay its global offering and listing of H-shares due to current market conditions [8] - Aipeng Medical announced a plan for a shareholder to reduce holdings by up to 1% of total shares, citing personal funding needs [12] - Hendi Pharmaceutical's shareholders plan to collectively reduce their holdings by up to 2.33% of total shares for personal financial planning [13] Financial Adjustments - Baihua Pharmaceutical plans to use 1.91 billion yuan from its capital reserve to cover losses, primarily due to goodwill impairment from a previous major asset restructuring [14]

Core Viewpoint - The major shareholder of Aipeng Medical, Beijing Zhanghong Private Fund Management Co., Ltd., plans to reduce its holdings in the company due to funding needs, with a total reduction of up to 252,090 shares, which is approximately 2.1% of the total share capital [1][2]. Group 1: Shareholder Reduction Plan - The shareholder, Zhanghong Selected No. 1 Private Securities Investment Fund, holds 5.6% of the company's total shares and intends to reduce its holdings by up to 126,050 shares through centralized bidding and another 126,050 shares through block trading [2]. - The reduction is based on market prices and is expected to take place within three months after the announcement [2]. Group 2: Financial Performance - In the first three quarters of the year, Aipeng Medical reported a revenue of 252 million yuan, a year-on-year decrease of 8.41%, and a net profit attributable to shareholders of -11.48 million yuan, a decline of 401.64% [3]. - The third quarter showed a net profit of 7.89 million yuan, reflecting a year-on-year increase of 255.22% [3]. Group 3: Company Background - Aipeng Medical focuses on pain management and upper respiratory tract management, while also expanding into intelligent medical device ecosystems and innovative businesses such as brain-machine interfaces and rapid rehabilitation [3]. - The company has a stake in Changzhou Ruishen'an Medical Device Co., Ltd., which specializes in the research, production, and sales of medical devices related to brain nerve regulation [3].

Core Viewpoint - Aipeng Medical (300753.SZ) experienced a significant price fluctuation, rising over 16% before a midday drop of nearly 6%, with its stock price falling below 29 yuan [1] Summary by Relevant Sections Shareholder Actions - Shareholder Beijing Zhanghong Private Equity Fund Management Co., Ltd. plans to reduce its holdings by no more than 2.52 million shares, which represents up to 2% of the company's total share capital [1] - The company has announced a total of five share reduction plans in the past three years [1] Market Reaction - The stock's midday decline followed a substantial increase earlier in the trading session, indicating volatility in investor sentiment [1] - The announcement of the share reduction may have contributed to the stock's price drop [1]

Group 1: Company Announcements - Zhejiang Dongri clarifies that it is not involved in "brain-computer interface" business [1] - Sanyuan Co. introduces seasonal product "milk candy hawthorn," which has a minimal revenue contribution [1] - Century Huatong plans to repurchase shares worth between 500 million to 1 billion [1] Group 2: Project Investments - Yongrong Co. intends to establish a subsidiary to build a 100 MW photovoltaic power station [1] - Weigao Medical plans to invest in a production base for all-cotton water-jet non-woven fabric [1] - Fuchun Environmental plans to invest in a combined heat and power project in Yicheng, Hubei [1] - Haibo Co. aims to invest in high-end components for flywheel energy storage [1] Group 3: Contract Awards - Longjian Co. wins a construction project worth 483 million [1] - Zhejiang Jiaoke is part of a consortium that aims to win a new urbanization project along the Fuchun River [1] - Dash Smart wins the intelligent project for the new Hong Kong Port inspection building [1] Group 4: Equity Transfers - Aerospace Intelligent Equipment plans to transfer 100% equity of its wholly-owned subsidiary Hangzhou Xuanyu [1] Group 5: Shareholding Changes - Aoxing Packaging's controlling shareholder plans to reduce holdings by up to 1.91% [2] - Aipeng Medical's Zhang Hong selected No. 1 intends to reduce holdings by up to 2% [2] - Ruimaite's senior executive Chen Bei plans to reduce holdings by up to 1.76% [3] - Changlian Co.'s director and general manager Xu Feng plans to reduce holdings by up to 206,520 shares [3] Group 6: Other Notable Events - Peking University Pharmaceutical's chairman and president Xu Xiren has been arrested on criminal charges [3] - Haibo Co. signs a strategic cooperation agreement with CATL, committing to procure no less than 200 GWh of electricity over the next three years [3]

Core Points - On November 12, Century Huatong announced a share repurchase plan of 500 million to 1 billion yuan for capital reduction [1][2] - A total of 18 A-share listed companies disclosed share reduction plans, indicating a trend of shareholder divestment [1][2] Summary of Share Repurchase - Century Huatong plans to repurchase shares worth between 500 million and 1 billion yuan to reduce registered capital [2] Summary of Share Reductions - Tai Xiang Co. plans to reduce no more than 1% of its shares by shareholder Zhongyuan Investment [2] - Jiang Bolong's second-largest shareholder has completed a reduction of 4.1915 million shares [2] - Senior management of Zhejiang Zhongcheng plans to reduce their holdings [2] - Controlling shareholder of Hexing Packaging intends to reduce no more than 1.91% of shares [2] - Shareholder Wang Ge of Dongfang Zhongke plans to reduce no more than 0.51% of shares [2] - Executive Yu Qingchi of Kuai Publishing plans to reduce no more than 0.02% of shares [2] - Directors and executives of Changlian Co. plan to collectively reduce no more than 0.77% of shares [2] - China Unicom's structural adjustment fund reduced 40.7003 million shares from November 10 to November 12 [2] - Shareholder Chen Bei of Ruimaite plans to reduce no more than 1.76% of shares [2] - Shareholder Zhang Hong of Aipeng Medical plans to reduce no more than 2% of shares [2] - Director Wo Jinye of Jujiao Co. plans to reduce no more than 0.01% of shares [2] - Directors and executives of Zhonglan Environmental Protection plan to reduce their holdings [2] - Shareholders Ning Kangqi and Beikangqi of Hendi Pharmaceutical plan to collectively reduce no more than 2.33% of shares [2] - Wuxi High-tech Zone New Momentum Industry Development Fund reduced 549,200 shares of Xiangnan Chip [2] - Controlling shareholder of Tianji Co. sold 8.4 million shares during a period of significant stock trading volatility [2] - The second-largest shareholder of Fangzheng Electric reduced a total of 1.6324 million shares on November 10 and 12 [2] - Controlling shareholder of Haodangjia plans to reduce no more than 2.7% of shares [2] - Controlling shareholder of Zhibang Home reduced 905,000 convertible bonds [2]

Core Insights - The brain engineering sector is leading the market with a rise of 1.05% [1] Company Performance - Aipeng Medical saw a significant increase of 7.51% [1] - Innovation Medical experienced a rise of 4.41% [1] - Century Huatong increased by 3.41% [1] - Chengyitong, Xiangyu Medical, and Sanbo Brain Science all rose by over 2% [1]

Core Viewpoint - Aipeng Medical (300753) announced that its shareholder, Beijing Zhanghong Private Equity Fund Management Co., Ltd. - Zhanghong Selected No. 1 Private Securities Investment Fund, plans to reduce its stake by up to 2% of the company's shares [1] Summary by Category Shareholder Actions - Zhanghong Selected No. 1 plans to reduce its holdings by no more than 1.26 million shares, which represents 1% of the total share capital of the company, through centralized bidding within three months after a 15 trading day period following the announcement [1] - Additionally, the fund intends to reduce another 1.26 million shares, also representing 1% of the total share capital, through block trading within the same timeframe [1] Current Holdings - As of the announcement, Zhanghong Selected No. 1 holds 7.058 million shares, accounting for 5.6% of the company's total share capital [1]

Core Viewpoint - Aipeng Medical (300753.SZ) announced that its major shareholder, Beijing Zhanghong Private Fund Management Co., Ltd., plans to reduce its holdings in the company through both centralized bidding and block trading methods, affecting a total of up to 252,100 shares, which represents 1% of the company's total share capital [1] Group 1 - The shareholder, Zhanghong Selected No. 1 Private Securities Investment Fund, intends to reduce its holdings by up to 126,050 shares through centralized bidding within three months after a 15 trading day period from the announcement [1] - Additionally, the same shareholder plans to reduce its holdings by up to 126,050 shares through block trading within the same timeframe [1]